A recent medical technique, known as less invasive surfactant administration (LISA), has been developed for treatment of lung disease or respiratory distress syndrome among premature babies.
A recent medical technique, known as less invasive surfactant administration (LISA), has been developed for treatment of lung disease or respiratory distress syndrome among premature babies.
LISA has been developed as a lung protective strategy for respiratory management and ventilation in view of the mechanical ventilation causing damage to the preterm lungs of newborns.
The procedure, started initially for newborn children with the birth weight of less than 1,500 grams, has yielded encouraging results.
Infants considered suitable for LISA are those being managed with primary continuous positive airway pressure (CPAP) or high flow with the evidence of increasing respiratory distress and with a rising oxygen requirement.
The regular application of LISA would turn out to be very useful and help save the lives of premature babies.